Emergent BioSolutions Inc. (EBS) stock: key figures, P/E, revenue and dividend
Health Care · United States · ISIN US29089Q1058
Emergent BioSolutions Inc. financials
| Fiscal year | 2025 |
|---|---|
| Revenue | 742.90 m USD |
| Gross profit | 416.70 m USD |
| Operating income | 100.10 m USD |
| EBIT | 142.10 m USD |
| Net income | 52.60 m USD |
| Diluted EPS – continuing operations | 0.93 USD |
Full history since 2001, charts and your own formulas
This page shows the last two fiscal years. After free sign-up you get the full income statement, balance sheet and cash flow, price and dividend charts, your own formula metrics and a stock screener covering more than 8,000 companies.
About Emergent BioSolutions Inc.
Emergent BioSolutions Inc., a life sciences company, provides preparedness and response solutions for accidental, deliberate, and naturally occurring public health threats in the United States, Canada, and internationally. It operates through Commercial Products, MCM Products, and All Other Revenues segments. The company offers ACAM2000, a smallpox and mpox vaccine; Anthrax Immune Globulin Intravenous (ANTHRASIL), a polyclonal antibody therapeutic for the treatment of inhalational anthrax; Botulism Antitoxin Heptavalent (BAT), an equine plasma antitoxin for the treatment of symptomatic botulism; BioThrax, an anthrax vaccine; CYFENDUS, a vaccine for post-exposure prophylaxis of disease following suspected or confirmed exposure to Bacillus anthracis; Ebanga, a monoclonal antibody for the treatment of infection caused by Orthoebolavirus zairense; Raxibacumab injection, a monoclonal antibody therapeutic for the treatment and prophylaxis of inhalational anthrax due to Bacillus anthracis; TEMBEXA, an oral antiviral for the treatment of smallpox disease caused by variola virus in adult and pediatric patients; and CNJ-016, a polyclonal antibody therapeutic to address complications from smallpox vaccination. It also provides NARCAN and KLOXXADO nasal sprays for the emergency treatment of known or suspected opioid overdose. In addition, the company offers contract development and manufacturing services comprising drug substance and product manufacturing, and packaging, as well as technology transfer, process, analytical development, and suite reservation services. Emergent BioSolutions Inc. was incorporated in 1998 and is headquartered in Gaithersburg, Maryland.
More stocks
- Samchully (004690.KS)
- NI Holdings, Inc. (NODK)
- Guangdong Jialong Food Co Ltd (002495.SZ)
- Angi Inc. (ANGI)
- Beijing Jiaman Dress Co. Ltd. A (301276.SZ)
- Tianjin Guifaxiang 18th Street Mahua Food Co Ltd (002820.SZ)
- Guangdong Hongming Intelligent Joint Stock Co. Ltd. (301105.SZ)
- Road Environment Technology Co. Ltd. A (688156.SS)
- TCI Co Ltd (8436.TWO)
- Chieftek Precision Co Ltd (1597.TW)
- MUNCY COLUMBIA FINANCIAL Corp (CCFN)
- Global Indemnity Group, LLC (GBLI)
Not investment advice. All data without warranty, price as of 29.10.2026. Details in the risk notice.